MX386473B - Formas solidas de un inhibidor de cdk4/6 selectivo - Google Patents

Formas solidas de un inhibidor de cdk4/6 selectivo

Info

Publication number
MX386473B
MX386473B MX2019003605A MX2019003605A MX386473B MX 386473 B MX386473 B MX 386473B MX 2019003605 A MX2019003605 A MX 2019003605A MX 2019003605 A MX2019003605 A MX 2019003605A MX 386473 B MX386473 B MX 386473B
Authority
MX
Mexico
Prior art keywords
inhibitor
solid forms
selective cdk4
dosage forms
free base
Prior art date
Application number
MX2019003605A
Other languages
English (en)
Other versions
MX2019003605A (es
Inventor
Brian Patrick Chekal
Nathan D Ide
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50151343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX386473(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of MX2019003605A publication Critical patent/MX2019003605A/es
Publication of MX386473B publication Critical patent/MX386473B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se relaciona con la base libre cristalina de acetil-8-ciclopentil-5-metil-2-(5-piperazin-1-il-piridin-2-ilamino)-8H-pirido[2,3-d]pirimidin-7-ona que tiene propiedades mejoradas, con composiciones farmacéuticas y formas de dosificación que comprenden la base libre, y con métodos para elaborar y utilizar tales compuestos, composiciones y formas de dosificación en el tratamiento de enfermedades proliferativas celulares, tales como cáncer.
MX2019003605A 2013-02-21 2014-02-08 Formas solidas de un inhibidor de cdk4/6 selectivo MX386473B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361767761P 2013-02-21 2013-02-21
PCT/IB2014/058865 WO2014128588A1 (en) 2013-02-21 2014-02-08 Solid forms of a selective cdk4/6 inhibitor

Publications (2)

Publication Number Publication Date
MX2019003605A MX2019003605A (es) 2019-06-17
MX386473B true MX386473B (es) 2025-03-18

Family

ID=50151343

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019003605A MX386473B (es) 2013-02-21 2014-02-08 Formas solidas de un inhibidor de cdk4/6 selectivo
MX2015010858A MX363715B (es) 2013-02-21 2014-02-08 Formas solidas de un inhbidor de cdk4/6 selectivo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015010858A MX363715B (es) 2013-02-21 2014-02-08 Formas solidas de un inhbidor de cdk4/6 selectivo.

Country Status (24)

Country Link
US (2) US20160002223A1 (es)
EP (2) EP3431475B1 (es)
JP (3) JP6381016B2 (es)
KR (2) KR20150107872A (es)
CN (3) CN107759594A (es)
AR (1) AR094842A1 (es)
AU (1) AU2014220354B2 (es)
BR (1) BR112015019508A8 (es)
CA (1) CA2900322C (es)
CY (2) CY1120734T1 (es)
DK (2) DK3431475T3 (es)
ES (2) ES2869277T3 (es)
HK (2) HK1211032A1 (es)
HU (2) HUE040434T2 (es)
IL (1) IL240277B (es)
MX (2) MX386473B (es)
PL (2) PL3431475T3 (es)
PT (2) PT3431475T (es)
RU (1) RU2619944C2 (es)
SG (1) SG11201505680RA (es)
SI (2) SI2958916T1 (es)
TR (1) TR201816077T4 (es)
TW (2) TWI670269B (es)
WO (1) WO2014128588A1 (es)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2872491T (lt) 2012-07-11 2021-08-25 Blueprint Medicines Corporation Fibroblasto augimo faktoriaus receptoriaus inhibitoriai
PT3431475T (pt) * 2013-02-21 2021-05-13 Pfizer Formas sólidas de um inibidor de cdk4/6 seletivo
RU2704112C2 (ru) 2013-10-25 2019-10-24 Блюпринт Медсинс Корпорейшн Ингибиторы рецептора фактора роста фибробластов
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
US20170240543A1 (en) * 2014-08-14 2017-08-24 Sun Pharmaceutical Industries Limited Crystalline forms of palbociclib
EP3186252A1 (en) * 2014-08-28 2017-07-05 ratiopharm GmbH Method of producing palbociclib and pharmaceutical compositions comprising the same
CN105616418A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂的药物制剂及其制备方法
WO2016090257A1 (en) * 2014-12-05 2016-06-09 Crystal Pharmatech Inc. Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
WO2016092442A1 (en) * 2014-12-08 2016-06-16 Sun Pharmaceutical Industries Limited Processes for the preparation of crystalline forms of palbociclib acetate
CN104610254B (zh) * 2015-01-26 2017-02-01 新发药业有限公司 一种帕博赛布的低成本制备方法
CZ201589A3 (cs) 2015-02-11 2016-08-24 Zentiva, K.S. Pevné formy soli Palbociclibu
EP3078663A1 (en) 2015-04-09 2016-10-12 Sandoz Ag Modified particles of palbociclib
WO2016156070A1 (en) 2015-04-02 2016-10-06 Sandoz Ag Modified particles of palbociclib
CN106117199A (zh) * 2015-05-04 2016-11-16 江苏恒瑞医药股份有限公司 一种细胞周期蛋白依赖性激酶抑制剂的二羟乙基磺酸盐、其结晶形式及其制备方法
AU2016272881C1 (en) * 2015-06-04 2019-10-03 Pfizer Inc. Solid dosage forms of palbociclib
CN106317053A (zh) * 2015-06-29 2017-01-11 北大方正集团有限公司 一种帕博昔布晶型a的制备方法
CN106397431A (zh) * 2015-07-28 2017-02-15 苏州国匡医药科技有限公司 一种抗肿瘤药物的新晶型及其制备方法和用途
CN105153149B (zh) * 2015-07-29 2017-09-19 江苏中邦制药有限公司 一种选择性激酶抑制剂Palbociclib的制备方法
SI3331881T1 (sl) * 2015-08-05 2019-08-30 Ratiopharm Gmbh Nova kristalna oblika in adukti palbocikliba in matanojske kisline
CN105085517B (zh) * 2015-08-06 2016-11-23 天津华洛康生物科技有限公司 一种结晶型帕博西尼游离碱水合物及其制备方法
SG10201913989QA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN106608876B (zh) * 2015-10-21 2018-06-19 新发药业有限公司 一种高纯度帕博西尼的制备方法
HU230962B1 (hu) 2015-10-28 2019-06-28 Egis Gyógyszergyár Zrt. Palbociclib sók
CN106632311B (zh) * 2015-11-02 2021-05-18 上海科胜药物研发有限公司 一种帕博西尼晶型a和晶型b的制备方法
CN106831759A (zh) * 2015-12-03 2017-06-13 上海星泰医药科技有限公司 帕布昔利布及其中间体的制备方法
CN105541832A (zh) * 2015-12-15 2016-05-04 南京艾德凯腾生物医药有限责任公司 一种羟乙基磺酸盐帕布昔利布的制备方法
WO2017115315A1 (en) * 2015-12-30 2017-07-06 Dr. Reddy's Laboratories Limited Solid forms of palbociclib
CN105524059A (zh) * 2016-01-06 2016-04-27 北京修正创新药物研究院有限公司 一种帕波西比杂质的制备方法
WO2017130219A1 (en) 2016-01-25 2017-08-03 Mylan Laboratories Limited Amorphous solid dispersion of palbociclib
GB201601329D0 (en) 2016-01-25 2016-03-09 Mohammad Mohammad A Inverse gas chromatography standard solutions, device and method
WO2017145054A1 (en) * 2016-02-24 2017-08-31 Lupin Limited Modified particles of crystalline palbociclib free base and process for the preparation thereof
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN106336411B (zh) * 2016-04-27 2018-03-06 上海医药集团股份有限公司 Cdk4/6抑制剂帕博西尼高纯度原料药的制备工艺及用途
CN109661393A (zh) 2016-05-08 2019-04-19 上海诚妙医药科技有限公司 帕布昔利布的新晶型及其制备方法及其用途
CN105924439B (zh) * 2016-06-24 2017-11-24 石家庄海瑞药物科技有限公司 一种帕布昔利布的制备方法
CN106146494B (zh) * 2016-06-29 2018-02-06 重庆华邦制药有限公司 用于制备帕布昔利布a型晶的溶剂及制备方法
EP3481825A1 (en) 2016-07-07 2019-05-15 Plantex Ltd. Solid state forms of palbociclib dimesylate
CN106220626A (zh) * 2016-07-31 2016-12-14 合肥远志医药科技开发有限公司 一种帕布昔利布的多晶型及其制备方法
CN106220627A (zh) * 2016-07-31 2016-12-14 合肥远志医药科技开发有限公司 一种高纯度帕布昔利布的工业化制备方法
US10233188B2 (en) 2016-08-15 2019-03-19 Pfizer Inc. CDK2/4/6 inhibitors
US20190192522A1 (en) 2016-09-08 2019-06-27 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors
US10710999B2 (en) 2016-10-07 2020-07-14 Mylan Laboratories Limited Polymorph of an intermediate for palbociclib synthesis
WO2018073574A1 (en) 2016-10-20 2018-04-26 Cipla Limited Polymorphic forms of palbociclib
US10849903B2 (en) 2016-10-20 2020-12-01 Pfizer Inc. Anti-proliferative agents for treating PAH
CN108017630B (zh) * 2016-10-31 2022-10-11 上海创诺制药有限公司 一种小比表面积帕博西尼游离碱的制备方法
EP3541389A1 (en) 2016-11-16 2019-09-25 Pfizer Inc Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer
CN108117550B (zh) * 2016-11-29 2020-08-14 上海医药工业研究院 吡啶并[2,3-d]嘧啶类化合物的制备方法
KR102513448B1 (ko) 2016-12-16 2023-03-23 씨스톤 파마슈티컬즈 Cdk4/6 억제제
US20200054560A1 (en) * 2017-04-21 2020-02-20 Alnova Pharmaceuticals, Ltd. Palbociclib compositions and methods thereof
CN108864078B (zh) * 2017-05-10 2021-10-15 江苏豪森药业集团有限公司 帕博西尼晶型b的制备方法
JP7097438B2 (ja) 2017-07-11 2022-07-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
WO2019020715A1 (en) 2017-07-28 2019-01-31 Synthon B.V. PHARMACEUTICAL COMPOSITION COMPRISING PALBOCICLIB
IL272697B2 (en) 2017-08-18 2023-12-01 Adastra Pharmaceuticals Inc A polymorphic form of TG02
JP7100125B2 (ja) 2017-10-27 2022-07-12 フレゼニウス・カビ・オンコロジー・リミテッド リボシクリブおよびその塩の改善された調製のためのプロセス
CN109897034A (zh) * 2017-12-07 2019-06-18 南京卡文迪许生物工程技术有限公司 一种高纯度晶型a帕布昔利布及其制备方法和药物组合物
RU2020123665A (ru) 2018-01-08 2022-02-10 Г1 Терапьютикс, Инк. Преимущественные режимы дозирования g1т38
CN108586452A (zh) * 2018-01-12 2018-09-28 重庆市碚圣医药科技股份有限公司 一种帕博西尼中间体的合成方法
WO2019166928A1 (en) 2018-02-27 2019-09-06 Pfizer Inc. Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor
CN108299422B (zh) * 2018-02-28 2019-10-25 杭州福斯特药业有限公司 一种帕泊昔利布中间体的制备方法
AU2019269159A1 (en) 2018-05-14 2020-11-19 Pfizer Inc. Oral solution formulation
CN108558745A (zh) * 2018-05-17 2018-09-21 苏州莱克施德药业有限公司 一种帕博西林中间体的合成方法
SI3802529T1 (sl) 2018-05-24 2024-03-29 Synthon B.V. Postopek za izdelavo palbocikliba
WO2019238088A1 (zh) * 2018-06-13 2019-12-19 基石药业 吡啶并吡啶酮衍生物的盐型及晶型
EP3844276A2 (en) 2018-08-28 2021-07-07 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
JP6952747B2 (ja) 2018-09-18 2021-10-20 ファイザー・インク がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
CN113286592A (zh) 2018-10-24 2021-08-20 效应治疗股份有限公司 Mnk抑制剂的结晶形式
CN109336886A (zh) * 2018-12-07 2019-02-15 重庆三圣实业股份有限公司 一种帕博西尼的制备方法及其产品
MX2021008645A (es) * 2019-01-17 2021-08-19 Pfizer Forma cristalina de un inhibidor de cinasa ciclinodependiente (cdk).
WO2020157709A1 (en) 2019-02-01 2020-08-06 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
CA3141452A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
EP3976090A1 (en) 2019-05-24 2022-04-06 Pfizer Inc. Combination therapies using cdk inhibitors
CN110256424A (zh) * 2019-07-03 2019-09-20 武汉工程大学 一种帕博西尼关键中间体v的合成方法
CA3152401A1 (en) 2019-08-26 2021-03-04 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
CN110551063A (zh) * 2019-10-17 2019-12-10 山东邹平大展新材料有限公司 一种合成5-(n-boc-哌嗪-1-基)吡啶-2-胺的方法
TW202146017A (zh) 2020-03-05 2021-12-16 美商輝瑞股份有限公司 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合
FI4181920T3 (fi) 2020-07-15 2025-11-20 Pfizer Kat6-estäjämenetelmät ja yhdistelmät syövän hoitoon
EP4181919A1 (en) 2020-07-20 2023-05-24 Pfizer Inc. Combination therapy
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
WO2022091001A1 (en) 2020-10-29 2022-05-05 Pfizer Ireland Pharmaceuticals Process for preparation of palbociclib
CN112274493A (zh) * 2020-11-18 2021-01-29 石药集团中奇制药技术（石家庄）有限公司 一种哌柏西利胶囊的制备方法
CN112457311B (zh) * 2020-12-04 2022-07-12 江苏豪森药业集团有限公司 一种含有氯溴吡咯嘧啶酮结构化合物的制备方法
WO2022123419A1 (en) 2020-12-08 2022-06-16 Pfizer Inc. Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
CN112661753B (zh) * 2020-12-29 2022-06-03 山东铂源药业股份有限公司 一种帕布昔利布中间体的制备方法
CN112778303A (zh) * 2020-12-31 2021-05-11 武汉九州钰民医药科技有限公司 Cdk4/6激酶抑制剂shr6390的制备方法
CN112898299B (zh) * 2021-01-26 2021-11-26 山东铂源药业有限公司 一种帕布昔利布中间体的制备方法
US20220399123A1 (en) 2021-06-14 2022-12-15 Preh Holding, Llc Connected body surface care module
JP2024525740A (ja) 2021-07-16 2024-07-12 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド 小分子サイクリン依存性キナーゼ４／６（ｃｄｋ４／６）およびｉｋｚｆ２（ｈｅｌｉｏｓ）分解剤並びにその使用方法
CN113845520A (zh) * 2021-09-09 2021-12-28 安徽皓元药业有限公司 一种帕布昔利布乳清酸盐及其制备方法
CN113999227A (zh) * 2021-11-26 2022-02-01 常州大学 一种帕博西尼中间体的制备方法
AU2022408062B2 (en) 2021-12-10 2025-08-14 Eli Lilly And Company Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibitor
WO2023111810A1 (en) 2021-12-14 2023-06-22 Pfizer Inc. Combination therapies and uses for treating cancer
WO2023114264A1 (en) 2021-12-15 2023-06-22 Eli Lilly And Company Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer
CN114195784A (zh) * 2021-12-29 2022-03-18 斯坦德标准技术研究(湖北)有限公司 帕博西尼有关物质及其制备方法和应用
EP4302832A1 (en) 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing glucono delta lactone
EP4302755B1 (en) 2022-07-07 2025-08-20 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing an amino acid
CN119604288A (zh) 2022-07-29 2025-03-11 辉瑞大药厂 用于治疗癌症的包含kat6抑制剂的给药方案
TW202539669A (zh) 2022-08-31 2025-10-16 美商亞文納營運公司 雌激素受體降解劑之給藥方案
WO2024097206A1 (en) 2022-11-02 2024-05-10 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
WO2024133726A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
WO2024132652A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
WO2024201340A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
EP4689660A1 (en) 2023-03-30 2026-02-11 Pfizer Inc. Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof
WO2025051337A1 (en) 2023-09-06 2025-03-13 Afyx Development A/S Compositions and methods for treating and preventing oral cancer
TW202532065A (zh) 2023-12-04 2025-08-16 美商建南德克公司 治療乳癌之組合療法
WO2025202854A1 (en) 2024-03-27 2025-10-02 Pfizer Inc. Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer
WO2026025013A2 (en) 2024-07-26 2026-01-29 Pfizer Inc. Combination therapy using cdk4 inhibitors for cancer treatments

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
JPH11138004A (ja) * 1997-11-06 1999-05-25 Mitsui Chem Inc ニトリル水和用の銅触媒及びその調製方法
CA2401368A1 (en) * 2000-03-06 2001-09-27 Warner-Lambert Company 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
AP1767A (en) * 2002-01-22 2007-08-13 Warner Lambert Co 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones.
JP2004074041A (ja) * 2002-08-20 2004-03-11 Cabot Supermetal Kk フッ素の回収方法
JP2004149472A (ja) * 2002-10-31 2004-05-27 Sumitomo Chem Co Ltd 亜リン酸エステル類の結晶、及びその製造方法
BRPI0412516A (pt) 2003-07-11 2006-09-19 Warner Lambert Co sal isetionato de um seletivo inibidor cdk4
EP2298760B1 (en) * 2004-06-29 2015-08-05 Helsinn Healthcare S.A. Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
EP2069344A2 (en) 2006-09-08 2009-06-17 Pfizer Products Inc. Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
CA2695406A1 (en) * 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
TW201014830A (en) * 2008-09-30 2010-04-16 Theravance Inc Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
ES2557553T3 (es) * 2009-07-15 2016-01-27 Theravance Biopharma R&D Ip, Llc Forma de base libre cristalina de un compuesto de bifenilo
AU2010295717B2 (en) * 2009-09-20 2014-09-11 Abbvie Inc. ABT-263 crystalline forms and solvates for use in treating Bcl-2 protein related diseases
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
PH12013500934A1 (en) * 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
PT3431475T (pt) * 2013-02-21 2021-05-13 Pfizer Formas sólidas de um inibidor de cdk4/6 seletivo
US20170240543A1 (en) 2014-08-14 2017-08-24 Sun Pharmaceutical Industries Limited Crystalline forms of palbociclib

Also Published As

Publication number Publication date
ES2869277T3 (es) 2021-10-25
EP2958916B1 (en) 2018-09-12
IL240277B (en) 2019-10-31
SI2958916T1 (sl) 2018-11-30
EP3431475A1 (en) 2019-01-23
DK3431475T3 (da) 2021-05-25
US10723730B2 (en) 2020-07-28
PT2958916T (pt) 2018-11-21
PL3431475T3 (pl) 2021-09-13
HK1211032A1 (en) 2016-05-13
TWI633103B (zh) 2018-08-21
CY1124068T1 (el) 2022-05-27
MX2019003605A (es) 2019-06-17
TR201816077T4 (tr) 2018-11-21
CN105008357A (zh) 2015-10-28
EP2958916A1 (en) 2015-12-30
KR20170094012A (ko) 2017-08-16
KR101858913B1 (ko) 2018-05-16
TWI670269B (zh) 2019-09-01
BR112015019508A2 (pt) 2017-07-18
MX2015010858A (es) 2015-12-03
JP2014162794A (ja) 2014-09-08
HUE054212T2 (hu) 2021-08-30
JP6524152B2 (ja) 2019-06-05
CN111253394A (zh) 2020-06-09
RU2015132371A (ru) 2017-03-29
EP3431475B1 (en) 2021-04-07
JP2019116512A (ja) 2019-07-18
CN107759594A (zh) 2018-03-06
PT3431475T (pt) 2021-05-13
SI3431475T1 (sl) 2021-08-31
IL240277A0 (en) 2015-09-24
CY1120734T1 (el) 2019-12-11
MX363715B (es) 2019-03-29
NZ710138A (en) 2020-09-25
AR094842A1 (es) 2015-09-02
CA2900322C (en) 2019-03-26
HK1248217A1 (zh) 2018-10-12
KR20150107872A (ko) 2015-09-23
AU2014220354B2 (en) 2018-02-01
AU2014220354A1 (en) 2015-08-06
PL2958916T3 (pl) 2019-01-31
US20180065964A1 (en) 2018-03-08
JP6381016B2 (ja) 2018-08-29
SG11201505680RA (en) 2015-09-29
CA2900322A1 (en) 2014-08-28
US20160002223A1 (en) 2016-01-07
BR112015019508A8 (pt) 2019-11-19
TW201444834A (zh) 2014-12-01
RU2619944C2 (ru) 2017-05-22
TW201803872A (zh) 2018-02-01
JP2017186376A (ja) 2017-10-12
DK2958916T3 (en) 2018-11-12
HUE040434T2 (hu) 2019-03-28
WO2014128588A1 (en) 2014-08-28
ES2694787T3 (es) 2018-12-27

Similar Documents

Publication Publication Date Title
MX386473B (es) Formas solidas de un inhibidor de cdk4/6 selectivo
PH12015502615B1 (en) Chemical compounds
NZ630925A (en) Pyrazolopyrimidine compounds as kinase inhibitors
MX359418B (es) Pteridinas como inhibidores del receptor del factor de crecimiento de fribroblasto (fgfr).
MX336214B (es) Derivados de pirrolotriazinona como inhibidores de pi3k.
MY185666A (en) Anticancer pyridopyrazines via the inhibition of fgfr kinases
PH12012502334A1 (en) Heteroaryl imidazolone derivatives as jak inhibitors
MX349004B (es) Nuevos compuestos.
EA201290147A1 (ru) Пирроло[2,3-d]пиримидиновые соединения
MX368112B (es) Pirrolo- o pirazolopirimidinas covalentes reversibles utiles para el tratamiento del cancer y de enfermedades autoinmunitarias.
PH12014500103A1 (en) Pyridin-2(1h)-one derivatives as jak inhibitors
GB201205669D0 (en) Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
MX2015014234A (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
PH12015500813A1 (en) Pyrrolotriazinone derivatives as pi3k inhibitors
MX366899B (es) Nuevos compuestos.
MX2013010898A (es) Novedoso derivados de la pirimidina.
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MX2012009074A (es) Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.
TW201613864A (en) Novel compounds
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
WO2016010869A3 (en) FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS
TN2013000377A1 (en) Thieno [2, 3-d] pyrimidine derivatives and their use to treat arrhythmia